Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Soared Today

By Joe Tenebruso - Mar 31, 2021 at 9:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Researchers started a clinical trial to evaluate the biotech's new coronavirus vaccine candidate.

What happened

Shares of Moderna (MRNA -3.21%) surged 10.5% Wednesday after the National Institutes of Health (NIH) began testing the drugmaker's experimental COVID-19 variant vaccine. 

So what

Moderna's new vaccine is designed to protect against a coronavirus strain first identified in South Africa. The worrisome mutation -- which scientists warn could spread faster than earlier versions of the virus and be more resistant to currently authorized vaccines  -- has been detected in at least nine states in the U.S. 

The NIH's phase 1 study will evaluate the drug's efficacy and safety profile among 210 healthy adult volunteers. These participants will include 60 people who took part in Moderna's original coronavirus vaccine trial, as well as 150 people who have not yet been vaccinated. The NIH expects the study to be fully enrolled by the end of April.

A person is pointing to a digital stock chart that rises, then falls, then rises again.

Investors bid up Moderna's stock Wednesday. Image source: Getty Images.

"Preliminary data show that the COVID-19 vaccines currently available in the United States should provide an adequate degree of protection against SARS-CoV-2 variants," National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony Fauci said in a press release. "However, out of an abundance of caution, NIAID has continued its partnership with Moderna to evaluate this variant vaccine candidate should there be a need for an updated vaccine."

Now what

The U.S. Food and Drug Administration (FDA) is expected to accelerate the emergency authorization process for vaccines that defend against coronavirus variants. So, if it proves safe and effective, Moderna could bring its new COVID-19 vaccine to market relatively quickly. 

Moderna will likely have more to say to investors about its clinical trials during its upcoming virtual Vaccines Day event on April 14. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$137.71 (-3.21%) $-4.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.